Sign in to fuzzto save your conversations, follow your research and come back anytime.
Dishman Carbogen Amcis
DCAL
NSE
BSE
NSEBSESectorHealthcare
176.99
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Dishman Carbogen Amcis shows stabilizing segment margins and cost control, but faces sharp declines in consolidated revenue and profitability.
Marketable Molecules EBITDA margin recovered from 14.0% in Q2 FY26 to 18.6% in Q1 FY27 — segment profitability is stabilizing.
Consolidated EBITDA fell from ₹5,806 Cr in Q1 FY26 to ₹601 Cr in Q1 FY27 — operating cash generation is weak.
Marketable Molecules revenue mix expanded from 14.3% in Q1 FY26 to 21% in Q1 FY27 — growing contribution to overall sales.
Consolidated net revenue declined from ₹28,958 Cr in Q1 FY26 to ₹6,776 Cr in Q1 FY27 — top-line growth remains inconsistent.
Average daily trading volume in shares rose from 233,956 in Q2 FY26 to 584,965 in Q1 FY27 — stronger market liquidity.
PAT margin swung from 10.0% in Q2 FY26 to -8.5% in Q1 FY27 — bottom-line profitability is under severe pressure.
Consolidated cost of goods sold dropped from ₹2,056 Cr in Q1 FY26 to ₹1,142 Cr in Q1 FY27 — better input cost control.
FII shareholding dropped from 8.07% in Q2 FY26 to 6.86% in Q1 FY27 — foreign investors continue to reduce stakes.
DII shareholding grew from 1.37% in Q2 FY26 to 2.07% in Q1 FY27 — rising domestic institutional interest.
Market capitalization fell from ₹43,209 Cr in Q2 FY26 to ₹27,495 Cr in Q1 FY27 — valuation swings reflect market caution.